AMOXICILLIN AND CLAVULANATE POTASSIUM

Post-LOE

amoxicillin and clavulanate potassium

Teva

ANDAORALFOR SUSPENSION

Approved

Mar 2004

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

AMOXICILLIN AND CLAVULANATE POTASSIUM (amoxicillin and clavulanate potassium) by Teva is suspension, 600 mg/42. Approved for equal to 40 kg with: recurrent, persistent acute otitis media due to s, acute otitis media due to s and 5 more indications. First approved in 2004.

Drug data last refreshed 23h ago

Mechanism of Action

suspension, 600 mg/42.9 mg per 5 mL is an antibacterial drug [see Microbiology ( )].

Indications (8)

equal to 40 kg with: Recurrent persistent acute otitis media due to S acute otitis media due to S

Worked on AMOXICILLIN AND CLAVULANATE POTASSIUM at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.